Evidence map›Paper›PMID 34048776›Full record

ReviewClinical biochemistry2021

Canadian Society of Clinical Chemists (CSCC) consensus guidance for testing, selection and quality management of SARS-CoV-2 point-of-care tests.

Jennifer Taher, Edward W Randell, Saranya Arnoldo, Dana Bailey, Vincent De Guire, Sukhbir Kaur, Michael Knauer, Eleonora Petryayeva, Susan M Poutanen, Julie L V Shaw and 3 more

Abstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical biochemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jennifer TaherPathology and Laboratory Medicine, Sinai Health System, Toronto, Canada; University of Toronto, Laboratory Medicine and Pathobiology, Toronto, Canada.
Edward W RandellDepartment of Laboratory Medicine, Faculty of Medicine, Memorial University of Newfoundland, Newfoundland, Canada.
Saranya ArnoldoUniversity of Toronto, Laboratory Medicine and Pathobiology, Toronto, Canada; William Osler Health System, Brampton, Canada.
Dana BaileyDynacare, Brampton, Canada.
Vincent De GuireClinical Biochemistry, Maisonneuve-Rosemont Hospital, Optilab-CHUM Laboratory Network, Montreal, Canada; Biochemistry, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Canada.
Sukhbir KaurFraser Health Authority, Vancouver, Canada; Pathology and Laboratory Medicine, University of British Columbia, Canada.
Michael KnauerPathology and Laboratory Medicine, London Health Sciences Center, London, Canada; Pathology and Laboratory Medicine, University of Western Ontario, London, Canada.
Eleonora PetryayevaDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada.
Susan M PoutanenUniversity of Toronto, Laboratory Medicine and Pathobiology, Toronto, Canada; University of Toronto, Medicine, Toronto, Canada; University Health Network/Sinai Health Department of Microbiology, Toronto, Canada.
Julie L V ShawEastern Ontario Regional Laboratory Association, Canada; Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada.
Uvaraj UddayasankarLifelabs, Toronto, Canada.
Nicole White-Al HabeebLifelabs, Toronto, Canada.
Danijela KonforteLifelabs, Toronto, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesA consensus guidance is provided for testing, utility and verification of SARS-CoV-2 point-of-care test (POCT) performance and implementation of a quality management program, focusing on nucleic acid and antigen targeted technologies. DESIGN AND

methodsThe recommendations are based on current literature and expert opinion from the members of Canadian Society of Clinical Chemists (CSCC), and are intended for use inside or outside of healthcare settings that have varied levels of expertise and experience with POCT. RESULTS AND

conclusionsHere we discuss sampling requirements, biosafety, SARS-CoV-2 point-of-care testing methodologies (with focus on Health Canada approved tests), test performance and limitations, test selection, testing utility, development and implementation of quality management systems, quality improvement, and medical and scientific oversight.

Indexed as

CanadaCOVID-19HumansPoint-of-Care TestingPractice Guidelines as TopicQualitative ResearchQuality ImprovementSARS-CoV-2Societies, ScientificAntigenCOVID-19Nucleic acid amplification testPoint-of-care testingQuality managementSARS-CoV-2

Identifiers

PMID34048776
PMCPMC8144094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.